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ess: Pernilla.Glader@mSummary The inflammation of the lungs in chronic obstructive pulmonary disease
(COPD) is characterised by increased numbers of macrophages, neutrophils and T-
cells. Decline in lung function in these patients has been correlated to the number of
CD8+ T-cells present in the lung as well as to a decline in the ratio of CD4+/CD8+ T-
cells. Although systemic components are likely to be present, circulating lymphocyte
populations in COPD patients have not been well characterised. This study aimed at
correlating lung function to expression of five different T-cell activation markers on
peripheral blood CD4+ and CD8+ T-cells in COPD patients and matched smokers.
Furthermore, proportions of lymphocyte populations and degree of systemic T-cell
activation in COPD patients were compared to that in smokers and never-smokers.
Peripheral blood lymphocytes from six never-smokers, eight smokers and 17 smokers
with COPD were analysed using flowcytometry. The number of lymphocytes per
millilitre was higher in smokers than in never-smokers. No differences were found
between the three groups in regard to proportions of lymphocyte populations, but
the number of CD4+ T-cells in smokers was higher than in both never-smokers and
COPD patients. The degree of T-cell activation was similar in all patient groups;
however, a clear correlation between CD69 expression on CD4+ T-cells and lung
function (FEV1% of predicted) was found when examining current smokers, with or
without COPD. Elevated numbers of CD69+ CD4+ T-cells in blood thus seem to be
protective against airway obstruction in smokers while still exposed to cigarette
smoke, the main inducer of COPD.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserve
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Chronic obstructive pulmonary disease (COPD) is to
a large extent induced by cigarette smoking.
Inflammation in the lung results mainly in centrallyd.
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bronchiolitis3 and emphysema4,5 and a fall in lung
function. The local inflammation in COPD is con-
tinuously being studied and neutrophils, macro-
phages and T-cells have been found in increased
numbers in the lungs of COPD patients.6 Studies on
T-cells have shown a correlation between the
number of CD8+ T-cells and a decline in lung
function7,8 and the balance between CD4+ and
CD8+ T-cells in the lungs of these patients has been
shown to be altered, resulting in a decline in the
CD4/CD8 ratio.7
Alterations in the systemic compartment of these
patients is so far less understood, although
systemic components of the disease seems to be
present, with circulating neutrophils and mono-
cytes in COPD patients having altered expression of
integrins,9,10 proteases and cytokines11 when com-
pared to healthy subjects. Blood T-cells from COPD
patients have not been as well characterised as T-
cells in the lung; however, circulating T-cells have
shown less differences in lymphocyte composition
and CD4/CD8 T-cell ratio.12–14 A few studies have
been published on expression of activation markers
on blood T-cells in COPD patients and smo-
kers.12,13,15 In these studies no correlations to lung
function have been made.
The aim of this study was to relate lung function
to activation of CD4+ and CD8+ T-cells in peripheral
blood from a group of COPD patients and
a matched group of smokers. Using flowcyto-
metry analysis, CD4+ and CD8+ T-cells were
analysed in regard to their expression of CD25
(a-subunit of the IL-2 receptor), CD28 (important
co stimulatory molecule), CD29 (b-chain of very
late antigen), CD69 (early leukocyte activa-
tion marker) and CD45R0 (marker of memory
T-cells). In addition, possible differences in T-cell
activation between COPD patients, smokers
and a control group of never-smokers were studied
and lymphocyte cell counts and proportions of
T-cells, B-cells and NK-cells in the groups were
quantified.Table 1 Patient characteristics.
Variable Never-smokers
N 6
Females 6
Age (years) 60 (33–74)
FEV1/FVC % 79 (66–91)
FEV1% of predicted 104 (39–112)
Smoking (pack years) 0
Data presented as median values and ranges.Material and methods
Patient recruitment
Thirty-one patients undergoing surgery for sus-
pected lung cancer at Lund University Hospital
participated in the study. Patients were divided
into three groups, six never-smokers, eight smokers
without COPD (six ex-smokers and two current
smokers) and 17 smokers with COPD (ten ex-
smokers and seven current smokers). All patients
had non-reversible reduction of lung function (less
than 10% increase of FEV1 after bronchodilation)
and had been without symptoms of infections at
least 4 weeks prior to participating in the study.
None of the patients were treated with oral or
inhaled steroids. COPD patients had mild to
moderate COPD according to GOLD (Global Initia-
tive for Chronic Obstructive Lung Disease) stan-
dards.16 All subjects gave written informed consent
to participate in the study, which was approved by
Lund University Ethics Committee.
Patient characteristics
Characteristics of the patients are presented in
Table 1. There was no difference in age between
the groups. FEV1/FVC differed, due to definition of
COPD, between COPD patients and the two other
patient groups but did not differ between smokers
and never-smokers. FEV1% of predicted was as
expected lower in the COPD group than in the
smokers. One of the never-smokers, who had an
FEV1 value 39% of predicted, had kyfoscoliosis. The
number of pack years did not differ between
smokers and COPD patients.
Blood sampling and antibody staining
Blood was collected in 10ml EDTA tubes at a
hospital visit prior to surgery. Lymphocyte
cell counts were obtained using an automatedSmokers COPD patients
8 17
3 6
58 (49–68) 66 (57–76)
77 (71–88) 58 (41–70)
92 (77–144) 72 (43–95)
40 (22–63) 46 (27–66)
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Medical Electronics, Kobe, Japan). Blood samples
were also stained with antibodies conjugated to
FITC, PE and PE-Cy5 for three-colour flowcytometry
analysis. Antibodies were added to 100 ml of whole
blood and incubated at room temperature for
15min. The blood was then fixed and red blood
cells lysed using DAKO Utilyse (DAKO, Glostrup,
Denmark). The cells were washed and resuspended
in PBS-1% BSA. T-cells were detected using anti-
bodies against CD3, CD4 and CD8. Staining with CD4
and CD8 antibodies was combined with antibodies
against the T-cell activation markers CD25, CD28,
CD29, CD69 and CD45R0. NK cells were detected as
CD16, CD56 double positive cells present in the
lymphocyte gate, which was set up in forward/side
scatter. B-cells were detected as CD19 positive
cells present in the lymphocyte gate. All antibodies
were purchased from DAKO (Glostrup, Denmark) as
were the isotype controls used in this study.
Flowcytometry data were collected until 10 000
cells had been detected in the lymphocyte gate.
Statistics
Kruskal–Wallis one-way analysis of variance was
applied to evaluate differences between the three
groups. In the case of significant difference
between the groups (Po0:05), ad hoc analysis
between groups was done using Wilcoxon–Mann–
Whitney. Correlations between patients’ character-Table 2 Lymphocyte subpopulations (%).
Lymphocyte population Never-smokers
% CD3+ 63 (45–67)
% CD4+ 41 (33–52)
% CD8+ 17 (10–28)
CD4+/CD8+ ratio 2.6 (1.2–5.2)
% CD19+ 10 (3–19)
% CD16+CD56+ 7 (3–16)
Data presented as median values and ranges.
Table 3 Lymphocyte subpopulations ( 106 cells/ml bloo
Lymphocyte population Never-smokers
CD3+ 0.9 (0.5–1)
CD4+ 0.58 (0.36–0.83)
CD8+ 0.16 (0.12–0.36)
CD19+ 0.13 (0.045–0.25)
CD16+CD56+ 0.09 (0.045–0.24)
Data presented as median values and ranges.
Different from smokers (Po0:05).istics and blood profile was made using Spearman
Rank Correlation. Data in tables and text are
presented as median values and range.Results
Lymphocyte subpopulations
The lymphocyte subpopulation profile is presented
in Table 2. There were no significant differences in
the proportion of T-cells (CD3+), B-cells (CD19+) or
NK-cells (CD16+CD56+) between the groups.
Neither were there any differences between the
percentage of CD4+ and CD8+ T-cells and the CD4/
CD8 ratio did not differ between the groups. Cell
counts (cells/ml whole blood) are presented in
Table 3. The number of lymphocytes (Po0:01),
CD3+ cells (Po0:05) and CD4+ T-cells (Po0:05)
differed between smokers and never-smokers and
in CD4+ T-cells also between smokers and COPD
patients (Po0:05). No differences were seen
between the groups in regard to numbers of CD8+
T-cells, NK-cells or B-cells.T-cell activation markers
The expression of activation markers on CD4+ and
CD8+ T-cells is presented in Tables 4 and 5,Smokers COPD patients
70 (43–82) 72 (45–85)
53 (31–64) 50 (25–59)
17 (12–21) 23 (6–41)
3 (2.2–4.3) 2.5 (1–8.5)
8 (3–15) 8 (4–19)
8 (2–11) 9 (3–25)
d).
Smokers COPD patients
1.41 (0.9–2) 1.16 (0.5–1.8)
1.09 (0.61–1.54) 0.83 (0.34–1)
0.34 (0.24–0.48) 0.39 (0.084–0.9)
0.16 (0.072–0.35) 0.1 (0.056–0.4)
0.14 (0.032–0.28) 0.12 (0.042–0.53)
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Table 4 Activation markers on CD4+ T-cells (%).
Activation
marker
Never-
smokers
Smokers COPD
patients
CD25 5 (0–9) 9 (1–16) 10 (1–57)
CD28 98 (95–99) 98 (55–100) 97 (90–100)
CD29 67 (52–82) 68 (49–97) 78 (47–98)
CD69 12 (3–35) 27 (6–100) 20 (8–40)
CD45R0 71 (50–90) 79 (64–99) 80 (54–96)
Table 5 Activation markers on CD8+ T-cells (%).
Activation
marker
Never-
smokers
Smokers COPD
patients
CD25 1 (0–1) 2 (0–9) 2 (0–6)
CD28 49 (2–66) 62 (28–94) 54 (25–88)
CD29 82 (55–90) 84 (59–98) 86 (63–99)
CD69 32 (27–57) 36 (14–96) 31 (16–69)
CD45R0 57 (37–77) 55 (37–95) 53 (30–91)
Data presented as median values and ranges.
160
140
120
100
80
60
40
FE
V 1
 
%
 o
f p
re
d
5 55 105
% CD69+ of CD4+
165
145
125
105
85
65
45
FE
V 1
 
%
 o
f p
re
d
5 15 25 35 45
% CD69+ of CD4+
(A)
(B)
Systemic CD+ T-cell activation in COPD 1091respectively. There were no differences in expres-
sion of activation markers between the groups.Figure 1 (A, B) The percentage of CD4+ T-cells positive
for CD69 in a joined group of smokers and COPD patients,
containing both ex-smokers and current smokers, corre-
lated to FEV1% of predicted (rs ¼ 0:55, P ¼ 0:0065) (A).
The correlation was due to the current smokers that,
when used alone in the analysis, showed an even stronger
correlation between CD69 expression on CD4+ T-cells and
FEV1% of predicted (rs ¼ 0:93, P ¼ 0:0009) (B).Correlation of expression of activation
markers to lung function
The degree of association between expression of
any of the activation markers and FEV1% of
predicted was investigated among smokers. The
two groups smokers and COPD patients were joined
and any correlation between their expression of the
different markers and their values of FEV1% of
predicted was tested using Spearman rank correla-
tion. In CD8+ T-cells no activation markers corre-
lated to lung function. In CD4+ T-cells, however,
the expression of CD69 was positively correlated
with FEV1% of predicted (rs ¼ 0:55, P ¼ 0:0065).
The correlation was made using 23 out of 25
patients as the value of FEV1% of predicted was
missing in one of the smokers and insufficient lysis
of red blood cells made the analysis of the FACS
sample with CD69, CD4 staining impossible in one of
the COPD patients. Due to the correlation seen, the
group of smokers and COPD patients was divided
into ex-smokers and current smokers and correla-
tion between CD69 expression on CD4+ T-cells and
FEV1% of predicted was tested separately in the two
new groups. There was no correlation in the group
of ex-smokers, but in the group of current smokers
the correlation between CD69 expression on CD4+T-cells and FEV1% of predicted was strong
(rs ¼ 0:93, P ¼ 0:0009) (Fig. 1).Discussion
This study aimed to look for possible correlations
between the activation status of systemic T-cells in
smokers, with and without COPD, and lung func-
tion. In addition, we also studied possible differ-
ences in blood lymphocyte populations in COPD
patients as compared to matched smokers and
never-smokers. No differences in percentages of
lymphocyte populations or expression of T-cell
activation markers were found when comparing
the three groups. However, the number of lympho-
cytes, CD3+ cells and CD4+ T-cells was higher in
smokers than in never-smokers and a significant
positive correlation between CD69 expression on
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found in current smokers.
The pathology of COPD has mainly been studied
locally in the lungs. Quite a few studies on tissue,
BAL and sputum samples have shown differences in
T-cell populations between smokers and non-
smokers as well as between smokers and COPD
patients.8,13,17 In those studies CD8+ T-cells have
been found in higher levels in smokers and COPD
patients and the number of CD8+ T-cells has been
correlated with a decrease in lung function.7 Those
studies indicate that T-cells are involved in the
pathogenesis of COPD. However, the nature of
the involvement is still not fully clarified and the
recruitment of T-cells to the lung tissue in COPD
remains unexplored. Studies on blood from COPD
patients have not been able to confirm that
lymphocyte populations are altered systemically
in the disease. Lewis et al.14 studied the relation
between peripheral blood leukocyte counts and
respiratory symptoms in a cross-sectional general
population study, and found no correlations
between number of lymphocytes and respiratory
symptoms or lung function. When blood T-cells
from COPD patients and healthy subjects were
compared in a study by Majori et al.,15 no
differences in CD3+, CD4+, CD8+ or CD19+ lympho-
cyte populations were found. The study was con-
firmed by a study by Leckie et al.13 showing no
differences in blood CD4+ and CD8+ populations when
comparing COPD patients and healthy subjects. The
results in the present study, where no differences in
percentages of cells was seen between the patient
groups, are in line with these former studies. A study
by de Jong et al., showed that when subgroupning
COPD patients in regard to smoking habits, differ-
ences in the proportion of CD8+ T-cells in blood were
seen. The percentage of CD8+ T-cells was higher in
non-smoking COPD patients when compared to non-
smoking healthy subjects, but no difference was seen
when adding COPD patients who were current
smokers in to the statistical analysis.18 The reason
for the blunted CD8 levels in smoking COPD patients
could be due to higher numbers of CD4+ T-cells in the
blood of smokers, which is a well-documented
finding14,19,20–22 and which also was seen in the
present study. In addition to what have been
published before, the present study also showed
higher numbers of CD4+ T-cells in smokers than in
COPD patients.
Previous studies have not comprehensively ana-
lysed different activation markers on T-cells, and
have not always made a separation between
expression on CD4+ and CD8+ T-cells. In the present
study a panel of five activation markers was studied
and all analyses were made on both CD4+ and CD8+cells. There was no difference in expression of the
different activation markers between the patient
groups on either CD4+ or CD8+ T-cells. These
findings are supported by previous studies on
CD25,15 CD6913 and CD45R018 expression on T-cells
in blood from COPD patients and healthy subjects
where no differences between the groups were
found. Correlation between expression of activa-
tion markers on CD4+ and CD8+ cells and lung
function has not been studied in blood from COPD
patients before. In a study on asymptomatic male
smokers, Ekberg-Jansson et al.17 looked for corre-
lations between activation markers on CD3+ T-cells
and lung function but did not see any significant
correlations. In the present study, CD69 expression
on CD4+ T-cells in smokers and COPD patients
correlated to lung function measured as FEV1% of
predicted.
The correlation showed to be present in current
smokers rather than in ex-smokers. Elevated
numbers of CD69 expressing CD4+ peripheral T-
cells thus seem to protect smokers from obstruction
while ongoing exposure to cigarette smoke still is
present. In vitro studies on T-cell responses to
cigarette smoke extract have shown a significant
reduction in activation of both CD4+ and CD8+ T-
cells when exposed to low doses of cigarette smoke
extract.25 One could speculate that individuals
more resistant to the inhibitory effects of cigarette
smoke, retain the capability to activate their T-
cells while exposed to cigarette smoke, and there-
by get more resistant to developing airway ob-
struction. If the systemic activation levels reflect a
more general capability to mount a protective T-
cell response against airway infections, these
patients could be coping better with the reoccur-
ring infections often recorded in COPD patients.
This could be of importance for disease progres-
sion, since reoccurring exacerbations induced by
airway infections have been implicated as one of
the driving forces for a decline in lung function in
COPD patients.23 Whether the ability to retain CD69
expression on CD4+ T-cells in blood is related to a
higher degree of T-cell activation in the respiratory
compartment, or to a sustained CD4/CD8 ratio in
the lung tissue is not presently evident and needs to
be studied further.
Since this work is part of a larger study, including
samples of peripheral lung tissue, blood from patients
undergoing surgery for suspected lung cancer was
used. As the control groups in this study matches the
COPD group, in that they are also patients with
suspected lung cancer, possible differences seen in
flowcytometry analysis of the cells are probable to be
due to COPD rather than cancer. A possible effect of
the lung cancer can however not be ruled out, but
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blood from patients with primary lung cancer showed
no differences in activation of T-cells in the patients
when compared to healthy subjects.24 In addition,
our data from the control groups in this study do not
differ from data we have on blood from healthy
volunteers (data not shown). Further studies on the
matched tissue samples from the patients in this
study could answer questions about the degree of T-
cell activation at the local site of inflammation i.e.
the lung.
In summary, the present study shows that the
degree of T-cell activation might be altered in the
blood of COPD patients. An increased degree of
CD69 expression on CD4+ T-cells seems to protect
against lung function deterioration. Further studies
on how the expression of CD69 affects lung function
needs to be carried out in order to better under-
stand the link between T-cells and COPD pathology.References
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